CAS Number93479-97-1
SynonymsGlimpiride; Glimepiride; Grimepride; amary; AMARYL; GliMepiride COS; CLIMEPIRIDE; MFCD00878417; glimepirid; GliMperide; hoe490
Molecular FormulaC24H34N4O5S
Molecular Weight490.62
Purity98%
Density1.3±0.1 g/cm3
Boiling Point677.0±65.0 °C at 760 mmHg
Melting Point212.2-214.5 °C
AppearanceWhite crystal-like solid
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 93479-97-1 |
| Catalog No. | 2A-0202308 |
| Chinese Name | 格列美脲 |
| Synonyms | Glimpiride; Glimepiride; Grimepride; amary; AMARYL; GliMepiride COS; CLIMEPIRIDE; MFCD00878417; glimepirid; GliMperide; hoe490 |
| Molecular Formula | C24H34N4O5S |
| Molecular Weight | 490.62 |
| Purity | 98 |
| Density | 1.3±0.1 g/cm3 |
| Boiling Point | 677.0±65.0 °C at 760 mmHg |
| Melting Point | 212.2-214.5 °C |
| Appearance | White crystal-like solid |
| Water Solubility | DMSO: >10 mg/mL |
| Storage Condition | Sealed and stored in a cool, dry warehouse. |
| Application | Glimepiride (Amaryl) is a medium and long-acting sulfonylurea anti-diabetic compound with an ED50 of 182 μg/k. |
| HTC | 2935009090 |
| SMILES | [S](=O)(=O)(NC(=O)NC3CCC(CC3)C)c1ccc(cc1)CCNC(=O)N2CC(=C(C2=O)CC)C |
| InChI | 1S/C24H34N4O5S/c1-4-21-17(3)15-28(22(21)29)24(31)25-14-13-18-7-11-20(12-8-18)34(32,33)27-23(30)26-19-9-5-16(2)6-10-19/h7-8,11-12,16,19H,4-6,9-10,13-15H2,1-3H3,(H,25,31)(H2,26,27,30) |
| InChI Key | WIGIZIANZCJQQY-UHFFFAOYSA-N |
| NACRES Code | NA.24 |
| UNSPSC | 41116107 |
| MSDS | msds/10754_1_93479_97_1.pdf |
| Bioactivity | Glimepiride(Amaryl) is a medium-to-long acting sulfonylurea anti-diabetic compound with an ED50 of 182 μg/kg.Target: DPP4Glimepiride (Hoe 490) is a new sulfonylurea. After oral administration of Hoe 490 to rabbits, blood glucose was lowered 3.5 times more than after glibenclamide (HB 419) and after intravenous administration, 2.5 times more [1]. glimepiride decreased extracellular Aβ40 and Aβ42 levels. glimepiride may serve as a promising drug for the treatment of AD associated with diabetes [2]. glimepiride was generally associated with lower risk of hypoglycemia and less weight gain compared to other sulfonylureas. Glimepiride use may be safer in patients with cardiovascular disease because of its lack of detrimental effects on ischemic preconditioning [3].Clinical indications: Non-insulin dependent diabetesToxicity: Severe hypoglycemic reactions with coma; seizure or other neurological impairment. Related Catalog Signaling Pathways >> Others >> Others Research Areas >> Metabolic Disease References [1]. Geisen, K., Special pharmacology of the new sulfonylurea glimepiride. Arzneimittelforschung, 1988. 38(8): p. 1120-30. [2]. Liu, F., et al., Glimepiride attenuates Abeta production via suppressing BACE1 activity in cortical neurons. Neurosci Lett, 2013. 557 Pt B: p. 90-4. [3]. Basit, A., M. Riaz, and A. Fawwad, Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected]. Vasc Health Risk Manag, 2012. 8: p. 463-72. Chemical & Physical Properties Density 1.3±0.1 g/cm3 Boiling Point 677.0±65.0 °C at 760 mmHg Melting Point 212.2-214.5 °C Molecular Formula C24H34N4O5S Molecular Weight 490.616 Flash Point 363.2±34.3 °C Exact Mass 490.224976 PSA 133.06000 LogP 4.17 Vapour Pressure 0.0±2.2 mmHg at 25°C Index of Refraction 1.628 Storage condition Room temp Water Solubility DMSO: >10 mg/mL |
| Use of | Properties Articles71 Name glimepiride Synonym More Synonyms Glimepiride Biological Activity Related Catalog Signaling Pathways >> Others >> Others Research Areas >> Metabolic Disease References [1]. Geisen, K., Special pharmacology of the new sulfonylurea glimepiride. Arzneimittelforschung, 1988. 38(8): p. 1120-30. [2]. Liu, F., et al., Glimepiride attenuates Abeta production via suppressing BACE1 activity in cortical neurons. Neurosci Lett, 2013. 557 Pt B: p. 90-4. [3]. Basit, A., M. Riaz, and A. Fawwad, Glimepiride: evidence-based facts, trends, and observations (GIFTS). [corrected]. Vasc Health Risk Manag, 2012. 8: p. 463-72. Chemical & Physical Properties Molecular Formula C24H34N4O5S Exact Mass 490.224976 PSA 133.06000 Index of Refraction 1.628 Storage condition Room temp |
| Tax Rebate | 9.0% |
| Supervision | None MFN tariff: 6.5% Ordinary tariff: 35.0% |
| Transport Info | Product name: Purity: 99.0% |
| MSDS Transport Info | Module 14. Shipping information United Nations classification: inconsistent with United Nations classification standards UN number: not specified |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Gemcitabine hydrochloride | 122111-03-9 | 2A-9010705 |
| Gemifloxacin | 175463-14-6 | 2A-9010708 |
| Gentamicin B | 36889-15-3 | 2A-9010715 |
| Gestodene | 60282-87-3 | 2A-9010720 |
| Glibenclamide | 10238-21-8 | 2A-9010753 |
| Glipizide | 29094-61-9 | 2A-9010756 |
| Granisetron | 109889-09-0 | 2A-9010779 |
| Hydrocortisone | 50-23-7 | 2A-9010867 |
| Hydroxychloroquine sulfate | 747-36-4 | 2A-9010870 |
| Hydroxyprogesterone acetate | 302-23-8 | 2A-9010871 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS